Post-radiation/Post-chemotherapy syndrome is a complex of physical ailments associated with a disruption

of the immune system, which is experienced by every patient undergoing cancer therapy, which in itself leads to

a deterioration in physical conditions and often to death (e.g., 30% in the first 8 days).

Dimetixicone® successfully alleviates these conditions, promoting faster recovery and a return to a functional life.

Dimetixicone®—a groundbreaking drug designed to accelerate recovery after radiotherapy and chemotherapy. This collaboration represents a significant advancement in supportive care for cancer patients.

Purpose and Importance

The primary objective of Dimetixicone® is to address the severe post-chemotherapy and radiation syndrome that many cancers patients experience. With a growing need for treatments that not only alleviate the side effects of cancer therapies but also enhance overall recovery and immune function, Dimetixicone® aims to fill this critical gap. The drug's goals include promoting rapid recovery, inhibiting oncogenic cell activity, and preventing the spread of metastases.

·       Cancer patients are prone to relapse because the whole organism has been exhausted by the cancer and the activation of natural defences against it, but also because it has been severely damaged by chemotherapy and radiotherapy. It is well known that chemotherapy itself burns the lining of the organs, preventing the absorption of vital elements. This in turn reduces the body's vital functions. The body's immune response is also reduced. Dimetixicone® inhibits inflammatory tissue infiltration. It promotes normalization of fibrin formation processes, increases microcirculation in tissues, inhibiting erythrocyte aggregation, increases phagocyte activity, suppresses neutrophil chemotaxis and reduces the content of circulating immune complexes.

·       In this case, no matter how many vital elements are administered to the body - because the cell receptors are damaged and do not allow nutrients into the cell, condemning it to starvation, weakness and accelerated death. Dimetixicone®'s formula bypasses the cellular receptor and delivers nutrients directly to the cell, prolonging its life and functionality.

·       Cancer cells are known to resist the immune system and, with the help of the PD-LI protein molecule, they block the receptor on immune cells, thereby plunging the healthy cell into 'hibernation'. Dimetixicone® has a high level of cell permeability, which helps to forcefully awaken these cells.

Development and Composition

Dimetixicone® was developed through extensive preclinical and clinical studies to ensure its efficacy and safety. The formulation includes a combination of active fractions of propolis, a B vitamin complex, C2H6OS, ITM magnesium, and ionic trace elements and other.  These key ingredients were chosen for their synergistic effects on the immune system and their ability to penetrate biological membranes.

Key attributes of Dimetixicone® include:

• Analgesic and Anti-inflammatory Effects: The drug inactivates hydroxyl radicals and improves metabolic processes at inflammation sites, inhibits nociceptive impulses in peripheral neurons, and antagonizes the vascular effects of histamine, bradykinin, and prostaglandin E1.

• Antiseptic Properties: It exhibits moderate antiseptic qualities, further supporting recovery.

Clinical Efficacy

Clinical trials have demonstrated that Dimetixicone® effectively combats residual cancer cells and boosts natural immune defenses. Significant findings from these trials include:

• Enhanced Nonspecific Resistance: Patients showed improved tissue regeneration and increased cell permeability.

• Metabolic Benefits: The drug plays a crucial role in carbohydrate and mineral metabolism and exhibits significant choleretic properties.

• Inflammatory Response: Dimetixicone® effectively addresses multiple inflammatory processes of various etiologies and eliminates toxic protein formations, providing a pronounced analgesic effect.

Conclusion and Future Directions

The development of Dimetixicone® marks an important milestone in the supportive care of cancer patients. Its comprehensive benefits highlight its potential as a standard adjuvant treatment in the post-cancer recovery period. Looking ahead, future studies will focus on optimizing the formulation and exploring its use in other immune-related conditions. Further studies will focus on refining dosing regimens and better understanding the molecular mechanisms underlying its therapeutic effects depending on the stage and severity of the cancer, as well as the overall ability of the body to tolerate chemotherapy and radiotherapy in advanced stages.

The next iteration of Dimetixicone® will build on these promising results, aiming to increase its efficacy and expand treatment options for patients undergoing intensive cancer treatment. This innovation promises to significantly improve recovery outcomes, reduce early mortality, and improve the overall well-being of cancer patients, marking a turning point in the ongoing fight against cancer.